Teva Pharma Industries Ltd ADR (TEVA)vsUniverse Pharmaceuticals Inc (UPC)
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
UPC
Universe Pharmaceuticals Inc
$2.25
-1.43%
HEALTHCARE · Cap: $1.28M
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 96536% more annual revenue ($17.26B vs $17.86M). TEVA leads profitability with a 8.2% profit margin vs -20.6%. TEVA earns a higher WallStSmart Score of 73/100 (B).
TEVA
Strong Buy73
out of 100
Grade: B
UPC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Intrinsic value data unavailable for UPC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -7.2% — below average capital efficiency
Revenue declined 14.1%
Earnings declined 82.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bull Case : UPC
The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Bear Case : UPC
The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
TEVA profiles as a value stock while UPC is a turnaround play — different risk/reward profiles.
UPC carries more volatility with a beta of 1.57 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 29/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Universe Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?